Myriad Genetics (NASDAQ:MYGN – Get Free Report) will likely be releasing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of ($0.03) per share and revenue of $206.0260 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Myriad Genetics had a negative return on equity of 8.51% and a negative net margin of 48.24%.The business had revenue of $200.40 million for the quarter, compared to analysts’ expectations of $202.42 million. During the same quarter in the prior year, the company posted ($0.03) EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, analysts expect Myriad Genetics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
Myriad Genetics Price Performance
Shares of NASDAQ MYGN traded down $0.17 during trading on Tuesday, hitting $5.28. The company had a trading volume of 319,253 shares, compared to its average volume of 1,557,316. Myriad Genetics has a fifty-two week low of $3.53 and a fifty-two week high of $8.59. The firm has a market capitalization of $498.60 million, a price-to-earnings ratio of -1.22 and a beta of 1.64. The company has a quick ratio of 2.19, a current ratio of 2.40 and a debt-to-equity ratio of 0.36. The stock has a fifty day simple moving average of $5.02 and a two-hundred day simple moving average of $4.98.
Wall Street Analyst Weigh In
Read Our Latest Report on Myriad Genetics
Insider Activity at Myriad Genetics
In other news, Director Paul Bisaro bought 7,500 shares of the stock in a transaction dated Thursday, May 14th. The shares were acquired at an average price of $3.69 per share, with a total value of $27,675.00. Following the completion of the acquisition, the director directly owned 97,441 shares in the company, valued at approximately $359,557.29. The trade was a 8.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rashmi Kumar sold 15,000 shares of Myriad Genetics stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $4.46, for a total value of $66,900.00. Following the completion of the sale, the director directly owned 171,889 shares in the company, valued at $766,624.94. This represents a 8.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.90% of the company’s stock.
Hedge Funds Weigh In On Myriad Genetics
Several hedge funds have recently bought and sold shares of the company. Quarry LP boosted its position in shares of Myriad Genetics by 155.6% in the 4th quarter. Quarry LP now owns 4,365 shares of the company’s stock worth $27,000 after buying an additional 2,657 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Myriad Genetics by 2,333.3% in the second quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock valued at $25,000 after purchasing an additional 4,480 shares during the last quarter. Royal Bank of Canada increased its stake in shares of Myriad Genetics by 129.6% during the 4th quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock worth $31,000 after purchasing an additional 2,818 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Myriad Genetics during the 2nd quarter worth approximately $37,000. Finally, American Century Companies Inc. acquired a new position in shares of Myriad Genetics during the 2nd quarter worth approximately $55,000. 99.02% of the stock is owned by hedge funds and other institutional investors.
About Myriad Genetics
Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.
Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.
Featured Articles
- Five stocks we like better than Myriad Genetics
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
- 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?
- Whirlpool’s Report May Show How Frozen the Housing Market Really Is
- 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
